United States Influenza Vaccines Market Size, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031

United States Influenza Vaccines Market Size, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031

The influenza vaccines market in the United States was valued at US$ 3,962 billion in 2022 and is expected to reach US$ 8,347 billion by 2031, registering a CAGR of 8.6% during the forecast period.

Rapid market expansion is primarily due to increased research and development, the introduction of quadrivalent influenza vaccines, the aging population, and vaccine awareness. In addition, expanded recommendations from government and advisory bodies to get influenza vaccines are driving market growth in the United States.

Influenza is the second leading cause of death from vaccine-preventable disease in the United States after COVID-19. Rates of seasonal influenza infection are highest in children, but the risks for complications, hospitalizations, and deaths are higher in adults 65 years of age and older, children younger than 5 years, pregnant women, and people of any age with conditions that place them at increased risk for influenza complications.

The report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size, forecasts, and trends in the influenza vaccines market in the United States during 2018-2031. In addition, the report is a collective presentation of primary and secondary research findings.

Key Market Developments

The United States continues to be the world’s largest influenza vaccines market
Demand for influenza vaccines is expected to increase over the forecast period due to the pandemic COVID -19
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate
Novavax announces initiation of Phase 2 study for COVID-19 influenza combination vaccine and stand-alone influenza vaccine candidate
GSK and CureVac advance mRNA COVID-19 and influenza vaccine candidates
Seqirus receives a government contract to develop 2 influenza vaccines

This Well-Versed and Comprehensive United States Influenza Vaccines Market Research Report 2023 is Divided into 20 Chapters:

Chapter 1 contains a brief description of the market under study
Chapter 2 describes the research methodology of the study
Chapter 3 identifies key trends and prospects for the U.S. influenza vaccine market and draws key conclusions
Chapter 4 discusses the market scenario for influenza vaccines in the United States in terms of historical market values and projections through 2031
Chapter 5 analysis of adults and children in the United States vaccinated with influenza vaccines and projection through 2031
Chapter 6 highlights key market dynamics in the U.S. influenza vaccine market, including factors driving the market, prevailing barriers, potential opportunities, and future trends. This section also includes an analysis of the impact of the driving and restraining factors
Chapter 7 offers comprehensive insights into the latest pricing trends and analysis of the U.S. influenza vaccine market
Chapter 8 includes a comprehensive analysis of influenza vaccine production, supply, and distribution in the United States (by company)
Chapter 9 provides a complete overview of influenza vaccine distribution and demand in the United States
Chapter 10 investigates the effectiveness of influenza vaccines in the United States
Chapter 11 thorough evaluation of rapid diagnostic tests for influenza management
Chapter 12 carefully evaluates the distribution channel and technique of influenza vaccination in the United States
Chapter 13 characteristics of reimbursement structures in the influenza vaccine market in the united states
Chapter 14 detailed insights into the legal framework of the U.S. influenza vaccine market
Chapter 15 tracks competitive developments, approaches, recent industry developments, and mergers and acquisitions, collaboration, distribution, exclusivity, and licensing agreements.
Chapter 16 an informative study was conducted on promising influenza vaccines in clinical development.
Chapter 17 analyses recent clinical trials of the influenza vaccine
Chapter 18 and 19 provides the industry landscape and detailed profiles of key and promising companies operating in the influenza vaccine market in the United States. The companies have been profiled based on their key facts, business description, products and services, current vaccine portfolio, promising vaccines in clinical development, platform technology, and key developments.
Chapter 20, i.e. the appendix contains a brief overview of the company, a glossary, contact information, and the disclaimer section.

Key and Emerging Players in the U.S. Influenza Vaccines Market are Listed Below:

Sanofi Pasteur
GlaxoSmithKline (GSK)
Seqirus (CSL Limited)
AstraZeneca
Novavax
Medicago
Moderna Inc
Pneumagen
Daiichi–Sankyo
Altimmune
FluGen
Imutex
EpiVax, Inc
Versatope Therapeutics, Inc
BiondVax Pharmaceuticals Ltd.

The Most Important Questions are Answered in this Current 2023 Report:

What is the current size of the U.S. influenza vaccine market?
What will be the CAGR of the influenza vaccine market in the United States?
How many people will be vaccinated with flu vaccines in the U.S. between 2018 and 2031?
What percentage of people in the United States get vaccinated against influenza?
What are the main flu vaccines available in the United States?
What are the key drivers of the influenza vaccine market in the United States?
What are the major barriers to the influenza vaccine market in the United States?
What is the reimbursement pattern in the influenza vaccine market in the United States?
What is the regulatory framework for the influenza vaccine market in the United States?
What are the key deals and agreements in the United States influenza vaccine market?
What are the upcoming flu vaccines that will significantly impact the market in the future?
Who are the main market participants? What is happening with them, what revenues do they generate from vaccines, and what are the current developments and scenarios?
Who are the new players? What are their events, clinical developments, platform technologies, phases, and current developments?
How is the market likely to develop in the future?